April 30, 2013
Several presentations at the 3rd International Conference on Viral Hepatitis (ICVH 2013), which took place in late March in New York City, highlighted new findings on HCV/HIV coinfection.
Pablo Labarga (of Hospital Carlos III in Madrid, Spain) shared the outcomes of a retrospective analysis of a large cohort of coinfected patients followed by serial FibroScan (Abstract 8). After a median follow-up of 53 months, data showed that regression of liver fibrosis does occur after treatment with direct-acting antivirals. A major determinant of regression was sustained viral clearance following antiviral treatment.
Alison Boyle (from Chelsea and Westminster Hospital in London, presenting on behalf of her colleague Amena Ahmed) described initial clinical experiences with boceprevir for the treatment of 5 HIV/HCV-coinfected patients (Abstract 24). The examination showed virologic responses in all five patients, but also found significant treatment-related toxicities, including anemia, depression, fatigue and neutropenia. One patient died four weeks into treatment due to decompensated liver disease.
Valérie Martel-Laferrière, M.D., (from Icahn School of Medicine at Mount Sinai in New York) discussed a comparative analysis of 33 HIV/HCV-coinfected and 117 HCV-monoinfected patients at her medical school and Johns Hopkins University in Baltimore, Md. (Abstract 31). The analysis concluded that on-treatment virologic responses were comparable between the two groups. SVR data are still pending.
This is part of a series of articles summarizing ICVH 2013. Read the other articles in the series:
Benjamin Young, M.D., Ph.D., is the vice president and chief medical officer of the International Association of Providers of AIDS Care, one of the joint sponsors of ICVH 2013. Dr. Young is also an adjunct professor at the Josef Korbel School of International Studies at the University of Denver. Click here to read a more detailed bio of Dr. Young, which includes financial disclosure information.
No comments have been made.
|Using Saliva as Lube Can Cause Rectal Gonorrhea|
|This Week in HIV Research: Enzyme May Reduce Cardiovascular Disease Risk, and New Insights Into an HIV Vaccine|
|This Week in HIV Research: Determinants of Cognitive Impairment, and Discovery of 'Teenage' Broadly Neutralizing Antibody|
|FDA Approves Descovy, an Updated Version of Truvada -- But Not for PrEP|
|What Should the Next U.S. President Do to Advance the Fight Against HIV?|